Table 3.
Subgroup analyses for the outcome of relapse-free survival
| Subgroups | No. of studies | HR (95% CI) | I2 (P value) |
|---|---|---|---|
| Population | |||
| Children | 3 | 3.22 (1.68–6.18) | 57.6% (0.10) |
| Adult | 4 | 1.69 (1.02–2.80) | 69.5% (0.02) |
| Design | |||
| Prospective | 5 | 2.37 (1.12–5.01) | 77.7% (< 0.01) |
| Retrospective | 5 | 2.71 (1.58–4.64) | 73.5% (< 0.01) |
| Region | |||
| Europe | 5 | 2.38 (1.26–4.50) | 83.5% (< 0.01) |
| USA | 3 | 2.87 (1.35–6.10) | 56.7% (0.10) |
| Asia | 2 | 2.61 (0.66–10.40) | 75.6% (0.04) |
| Detection method | |||
| PCR | 5 | 2.09 (1.07–4.08) | 75.3% (< 0.01) |
| FC | 4 | 3.58 (1.73–7.40) | 73.8% (< 0.01) |
| Adjustment | |||
| Adjusted | 7 | 2.50 (1.64–3.82) | 64.4% (0.01) |
| Crude | 3 | 2.93 (0.81–10.64) | 86.3% (< 0.01) |